{"id":594,"date":"2026-09-15T10:51:37","date_gmt":"2026-09-15T07:51:37","guid":{"rendered":"https:\/\/ecomed.kz\/aktau\/laboratornye-issledovaniya\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/"},"modified":"2026-09-18T11:31:01","modified_gmt":"2026-09-18T08:31:01","slug":"signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence","status":"publish","type":"laboratory_test","link":"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/","title":{"rendered":"Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence"},"content":{"rendered":"<h2 class=\"wp-block-heading\">Signatera is a personalized molecular genetic test designed to detect circulating tumor DNA (ctDNA) in the blood of patients who have previously been diagnosed with cancer.<\/h2>\n<p class=\"wp-block-paragraph\">This test can be used to detect signs of minimal or molecular residual disease after surgery, monitor response to cancer treatment, or detect cancer recurrence following a period of remission.<\/p>\n<h2 class=\"wp-block-heading\"> <strong>What questions can the Signatera test answer?<\/strong><\/h2>\n<ul class=\"wp-block-list\">\n<li>Is there any cancer remaining in the body after surgery?<\/li>\n<li>Is the treatment effective?<\/li>\n<li>Is there a risk of cancer recurrence?<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\"><strong>Why is this important?<\/strong><\/h2>\n<ul class=\"wp-block-list\">\n<li>Because the Signatera\u2122 panel is developed individually based on each patient\u2019s tumor tissue, the test is highly sensitive and can detect microscopic fragments of tumor DNA present in the blood<\/li>\n<li>Signatera\u2122 enables longitudinal monitoring of ctDNA levels in real time, meaning that the test can identify the risk of recurrence earlier than standard imaging methods<\/li>\n<li>Understanding changes in ctDNA levels at the earliest stages supports more informed clinical treatment decisions<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">\n<h2 class=\"wp-block-heading\"><strong>How <mark class=\"has-inline-color\">Signatera\u2122<\/mark> works: A personalized and informed approach to monitoring<\/strong>.<\/h2>\n<ul class=\"wp-block-list\">\n<li>A one-time analysis of blood and tumor tissue identifies your unique set of tumor mutations.<\/li>\n<li>The test is individually designed and personalized specifically for you using your own tumor tissue.<\/li>\n<li>The Signatera\u2122 test can detect small fragments (molecules) of circulating tumor DNA each time it is ordered as part of your follow-up blood testing. Patients in whom circulating tumor DNA is detected (a positive Signatera result) are more likely to experience recurrence.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Benefits:<\/h2>\n<h3 class=\"wp-block-heading\"><strong><mark class=\"has-inline-color\">E<\/mark><\/strong><mark class=\"has-inline-color\"><strong>arly detection of recurrence<\/strong>:<\/mark><\/h3>\n<p class=\"wp-block-paragraph\">Signatera\u2122 testing protocols can detect circulating tumor DNA (ctDNA) significantly earlier than standard clinical assessments, with high sensitivity. In validation studies, molecular recurrence detected by Signatera\u2122 preceded clinical recurrence by:<\/p>\n<ul class=\"wp-block-list\">\n<li>an average of 8.7 months in colorectal cancer<\/li>\n<li>an average of 9.5 months in breast cancer<\/li>\n<li>an average of 4 months in lung cancer<\/li>\n<li>an average of 2.8 months in muscle-invasive bladder cancer<\/li>\n<li><strong><mark class=\"has-inline-color\">Is your treatment effective?<\/mark><\/strong> (for example, chemotherapy, radiation therapy, or immune checkpoint inhibitors)<\/li>\n<\/ul>\n<p class=\"wp-block-paragraph\">In addition, clinical studies conducted by the company showed that patients with a positive Signatera\u2122 result after surgery had poorer recurrence-free survival compared with patients who had a negative test result. This allows the test to be used for postoperative risk stratification and to support early clinical decision-making regarding the need for adjuvant chemotherapy and the timing of treatment escalation or dose adjustment. The high performance of the Signatera\u2122 test has been demonstrated across solid tumors.<a id=\"_msocom_1\"><\/a><\/p>\n<h3 class=\"wp-block-heading\"><mark class=\"has-inline-color\"><strong>Non-invasive testing<\/strong>:<\/mark><\/h3>\n<p class=\"wp-block-paragraph\">Using a simple blood test to monitor ctDNA reduces the need for more invasive procedures, such as biopsies, which are often difficult or impractical for regular monitoring.<\/p>\n<h3 class=\"wp-block-heading\"><mark class=\"has-inline-color\"><strong>Comprehensive information<\/strong>:<\/mark><\/h3>\n<p class=\"wp-block-paragraph\">Circulating tumor DNA analysis can provide a broad picture of the disease by identifying mutations and genetic alterations that may be driving the cancer, helping to guide subsequent therapy selection.<\/p>\n<h2 class=\"wp-block-heading\"><strong>Unique technology<\/strong><\/h2>\n<p class=\"wp-block-paragraph\">Not all <strong>circulating tumor DNA<\/strong> tests are <strong>equally accurate and effective<\/strong>, making it important to choose the most reliable methods. Signatera\u2122 is one of the most comprehensive tests available for detecting circulating tumor DNA in the blood. Read our peer-reviewed publications <a href=\"https:\/\/www.natera.com\/resource-library\/natera-publications\/signatera-publications\/\" data-type=\"link\" data-id=\"https:\/\/www.natera.com\/resource-library\/natera-publications\/signatera-publications\/\"><mark class=\"has-inline-color\">here.<\/mark><\/a><\/p>\n<h2 class=\"wp-block-heading\"><strong>Absolute test limitations<\/strong>:<\/h2>\n<ul class=\"wp-block-list\">\n<li>Testing cannot be performed in patients who have undergone bone marrow transplantation or received a blood transfusion within the past three months.<\/li>\n<li>Testing cannot be performed when a cancerous tumor is detected in an organ that was previously transplanted into the patient.<\/li>\n<li>Testing cannot be performed in patients who have undergone stem cell transplantation (SCT).<\/li>\n<li>Signatera has limited sensitivity for certain types of cancer, including gastrointestinal stromal tumors, renal cell carcinoma, primary brain tumors, and lymphoma, due to limited ctDNA shedding (each case is assessed individually, and consultation with the laboratory may be possible).<\/li>\n<li>Each Signatera test is designed for only one tumor type. If you have a history of two different cancers at the same time, you are advised to undergo two separate Signatera tests or to test the more aggressive of the identified cancers.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Signatera is a personalized molecular genetic test designed to detect circulating tumor DNA (ctDNA) in the blood of patients who have previously been diagnosed with cancer. This test can be used to detect signs of minimal or molecular residual disease after surgery, monitor response to cancer treatment, or detect cancer recurrence following a period of [&hellip;]<\/p>\n","protected":false},"featured_media":0,"menu_order":0,"template":"","class_list":["post-594","laboratory_test","type-laboratory_test","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence - \u0410\u043a\u0442\u0430\u0443<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/\" \/>\n<meta property=\"og:locale\" content=\"ru_RU\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence - \u0410\u043a\u0442\u0430\u0443\" \/>\n<meta property=\"og:description\" content=\"Signatera is a personalized molecular genetic test designed to detect circulating tumor DNA (ctDNA) in the blood of patients who have previously been diagnosed with cancer. This test can be used to detect signs of minimal or molecular residual disease after surgery, monitor response to cancer treatment, or detect cancer recurrence following a period of [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/\" \/>\n<meta property=\"og:site_name\" content=\"\u0410\u043a\u0442\u0430\u0443\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-18T08:31:01+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u041f\u0440\u0438\u043c\u0435\u0440\u043d\u043e\u0435 \u0432\u0440\u0435\u043c\u044f \u0434\u043b\u044f \u0447\u0442\u0435\u043d\u0438\u044f\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 \u043c\u0438\u043d\u0443\u0442\u044b\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/en\\\/laboratory-tests\\\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\\\/\",\"url\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/en\\\/laboratory-tests\\\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\\\/\",\"name\":\"Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence - \u0410\u043a\u0442\u0430\u0443\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/#website\"},\"datePublished\":\"2026-09-15T07:51:37+00:00\",\"dateModified\":\"2026-09-18T08:31:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/en\\\/laboratory-tests\\\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\\\/#breadcrumb\"},\"inLanguage\":\"ru-RU\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/en\\\/laboratory-tests\\\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/en\\\/laboratory-tests\\\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"\u0413\u043b\u0430\u0432\u043d\u0430\u044f \u0441\u0442\u0440\u0430\u043d\u0438\u0446\u0430\",\"item\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/#website\",\"url\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/\",\"name\":\"\u0410\u043a\u0442\u0430\u0443\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ecomed.kz\\\/aktau\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ru-RU\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence - \u0410\u043a\u0442\u0430\u0443","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/","og_locale":"ru_RU","og_type":"article","og_title":"Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence - \u0410\u043a\u0442\u0430\u0443","og_description":"Signatera is a personalized molecular genetic test designed to detect circulating tumor DNA (ctDNA) in the blood of patients who have previously been diagnosed with cancer. This test can be used to detect signs of minimal or molecular residual disease after surgery, monitor response to cancer treatment, or detect cancer recurrence following a period of [&hellip;]","og_url":"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/","og_site_name":"\u0410\u043a\u0442\u0430\u0443","article_modified_time":"2026-09-18T08:31:01+00:00","twitter_card":"summary_large_image","twitter_misc":{"\u041f\u0440\u0438\u043c\u0435\u0440\u043d\u043e\u0435 \u0432\u0440\u0435\u043c\u044f \u0434\u043b\u044f \u0447\u0442\u0435\u043d\u0438\u044f":"4 \u043c\u0438\u043d\u0443\u0442\u044b"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/","url":"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/","name":"Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence - \u0410\u043a\u0442\u0430\u0443","isPartOf":{"@id":"https:\/\/ecomed.kz\/aktau\/#website"},"datePublished":"2026-09-15T07:51:37+00:00","dateModified":"2026-09-18T08:31:01+00:00","breadcrumb":{"@id":"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/#breadcrumb"},"inLanguage":"ru-RU","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ecomed.kz\/aktau\/en\/laboratory-tests\/signatera-personal-molecular-test-to-monitor-minimal-residual-disease-mrd-and-early-detection-of-cancer-recurrence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"\u0413\u043b\u0430\u0432\u043d\u0430\u044f \u0441\u0442\u0440\u0430\u043d\u0438\u0446\u0430","item":"https:\/\/ecomed.kz\/aktau\/"},{"@type":"ListItem","position":2,"name":"Signatera Personal molecular test to monitor minimal residual disease (MRD) and early detection of cancer recurrence"}]},{"@type":"WebSite","@id":"https:\/\/ecomed.kz\/aktau\/#website","url":"https:\/\/ecomed.kz\/aktau\/","name":"\u0410\u043a\u0442\u0430\u0443","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ecomed.kz\/aktau\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ru-RU"}]}},"_links":{"self":[{"href":"https:\/\/ecomed.kz\/aktau\/wp-json\/wp\/v2\/laboratory_test\/594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ecomed.kz\/aktau\/wp-json\/wp\/v2\/laboratory_test"}],"about":[{"href":"https:\/\/ecomed.kz\/aktau\/wp-json\/wp\/v2\/types\/laboratory_test"}],"version-history":[{"count":1,"href":"https:\/\/ecomed.kz\/aktau\/wp-json\/wp\/v2\/laboratory_test\/594\/revisions"}],"predecessor-version":[{"id":1166,"href":"https:\/\/ecomed.kz\/aktau\/wp-json\/wp\/v2\/laboratory_test\/594\/revisions\/1166"}],"wp:attachment":[{"href":"https:\/\/ecomed.kz\/aktau\/wp-json\/wp\/v2\/media?parent=594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}